WHG
IOVA icon

Westwood Holdings Group’s Iovance Biotherapeutics IOVA Stock Holding History

Westwood Holdings Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,300
Closed -$147K – 455
2019
Q4 		$147K Buy
+5,300
New +$121K ﹤0.01% 453

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Westwood Holdings Group's IOVA Position: Q1 2020 in Review

Westwood Holdings Group sold out of Iovance Biotherapeutics (IOVA) in Q1 2020, closing a stake of 5,300 shares — an estimated $147K sold.

Westwood Holdings Group first reported a position in IOVA in Q4 2019 and held it in 1 quarter. The position peaked at $147K in Q4 2019. 219 funds tracked by Wall St. Rank hold IOVA as of Q1 2020.

  • Westwood Holdings Group reported no remaining Iovance Biotherapeutics position as of Q1 2020 after selling out during the quarter.
  • Westwood Holdings Group sold 5,300 Iovance Biotherapeutics shares in Q1 2020, an estimated $147K.
  • Westwood Holdings Group first reported a position in Iovance Biotherapeutics in Q4 2019 and held it in 1 quarter.
  • Westwood Holdings Group's Iovance Biotherapeutics position peaked at $147K in Q4 2019.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2020.

Based on Westwood Holdings Group's 13F filing for Q1 2020, filed 15 May 2020.